CD137 ELISA Kit Market Size, Share, Growth, and Industry Analysis, By Types (Human, Mouse, Rat, Others), By Applications Covered (Hospital, Research Institute, Others ), Regional Insights and Forecast to 2035

CD137 ELISA Kit Market Size

The Global CD137 ELISA Kit market size was valued at USD 12.2 Million in 2025, is projected to reach USD 13 Million in 2026, and is expected to hit approximately USD 13.9 Million by 2027, surging further to USD 23.8 Million by 2035. This remarkable expansion reflects a robust CAGR of 6.9% throughout the forecast period 2026-2035.

Global CD137 ELISA Kit Market is expanding due to the rising use of immunology testing, cancer biomarker research, and advanced laboratory diagnostics across research institutes and biotechnology companies. More than 64% of immunology laboratories have increased the use of ELISA-based assays, while over 58% of biotechnology research centers now rely on biomarker detection kits for immune response analysis. Around 72% of academic research projects studying immune checkpoint pathways include ELISA testing, supporting steady demand for the Global CD137 ELISA Kit Market across clinical and research applications.

The United States continues to strengthen its position through growing biomedical research investments and wider laboratory testing capabilities. US CD137 ELISA Kit Market is supported by increasing cancer immunotherapy studies, with more than 68% of oncology research laboratories using ELISA-based biomarker analysis and nearly 61% of life science organizations expanding immune assay testing for drug discovery and clinical research.

Japan CD137 ELISA Kit Market is witnessing healthy growth because of increasing biotechnology innovation, precision medicine programs, and strong government support for medical research. More than 66% of Japanese clinical research laboratories are investing in advanced immunoassay technologies, while nearly 57% of pharmaceutical development projects include immune biomarker evaluation using ELISA kits. Around 63% of university-based life science research facilities continue to adopt CD137-related testing for immune pathway studies, helping strengthen product demand across academic, diagnostic, and pharmaceutical research sectors throughout the country.

Key Findings

• Market Size: Valued at 13M in 2026, expected to reach 23.8M by 2035, growing at a CAGR of 6.9%.
• Growth Drivers: Immunotherapy studies influence 69% of demand, while biomarker testing supports 67% of pharmaceutical research and 64% of academic laboratory activity.
• Trends: Automated testing attracts 59% of laboratories, rapid assays interest 53%, and low-sample formats influence 57% of purchasing decisions.
• Key Players: Thermo Fisher, Abcam, Bio-Techne, Arigo Biolaboratories Corp., LifeSpan BioSciences, Inc.
• Regional Insights: Asia-Pacific holds 33% market share, North America 29%, Europe 26%, and Middle East & Africa 12%, totaling 100%.
• Challenges: Matrix interference affects 49% of laboratories, low concentrations concern 43%, and manual testing errors influence 41% of assay results.
• Industry Impact: Research institutes generate 52% of demand, hospitals hold 31%, and biotechnology, pharmaceutical, and contract laboratories account for 17%.
• Recent Developments: Rapid formats improve workflows by 28%, ultra-sensitive tools interest 43%, and automation-compatible assay demand reaches 49% among advanced laboratories.

CD137 ELISA Kit Market Trends

The CD137 ELISA Kit Market is experiencing significant transformation as immunology research, oncology diagnostics, and biotechnology innovation continue to expand across developed and emerging economies. More than 71% of research laboratories involved in immune checkpoint analysis now utilize ELISA technology because of its accuracy, reproducibility, and cost efficiency. Approximately 67% of pharmaceutical companies developing immunotherapy candidates perform routine immune biomarker screening during drug discovery, increasing the adoption of CD137 ELISA Kit Market products. Around 59% of biotechnology companies have expanded investments in immune assay platforms to improve research quality and laboratory productivity. The growing focus on personalized medicine has also influenced demand, with nearly 62% of precision medicine research projects incorporating biomarker-based immune testing. Academic institutions remain major contributors, as over 74% of university immunology departments continue to conduct CD137-related studies for T-cell activation and immune response evaluation. Digital laboratory management systems have improved testing workflows in approximately 55% of research facilities, reducing manual processing errors and improving laboratory efficiency. 

More than 60% of contract research organizations now include ELISA-based biomarker services within their research portfolios to meet increasing customer demand. Automated laboratory instruments have been integrated into nearly 53% of high-volume diagnostic laboratories, improving testing consistency and sample throughput. In addition, over 69% of cancer research programs continue exploring immune checkpoint biomarkers for developing targeted therapies, directly supporting long-term expansion of the CD137 ELISA Kit Market. Rising collaborations between biotechnology companies, academic institutions, and pharmaceutical manufacturers have increased by nearly 47%, accelerating product innovation and expanding commercial availability. Improved reagent quality, better assay sensitivity, and stronger laboratory quality control standards are further supporting market adoption, while more than 65% of global life science research organizations continue increasing spending on advanced immunological testing solutions.

CD137 ELISA Kit Market Dynamics

OPPORTUNITY

Expansion of Personalized Immunotherapy Research

The CD137 ELISA Kit Market has strong opportunities in personalized immunotherapy, immune profiling, and targeted cancer treatment research. Approximately 69% of oncology research teams are increasing their focus on immune checkpoint biomarkers, while 63% of precision medicine programs use protein-level testing to study patient-specific immune responses. Nearly 58% of biotechnology companies are expanding assay portfolios for T-cell activation analysis, creating wider demand for CD137 ELISA kits. Contract research organizations represent another opportunity, as 54% have added immunoassay services for pharmaceutical clients. Multiplex testing and high-sensitivity detection can further improve market adoption, with 61% of laboratory managers showing interest in assays that reduce sample use. Emerging research markets also offer potential because nearly 47% of life science laboratories plan to strengthen immunology testing capabilities.

DRIVERS

Rising Use of Immune Biomarker Testing

Growth in cancer immunology, drug discovery, and T-cell research is a major driver of the CD137 ELISA Kit Market. Around 72% of immuno-oncology laboratories use ELISA-based methods for protein detection, while 67% of pharmaceutical research teams include immune biomarker testing during preclinical studies. CD137 is closely linked with activated T-cells, making the assay useful in studies involving immune response, therapeutic antibodies, and checkpoint pathways. Nearly 64% of academic immunology departments conduct cytokine or receptor-level analysis, supporting regular kit consumption. Automated plate readers are used by approximately 59% of advanced laboratories, improving assay speed and repeatability. Demand is also strengthened by the growing use of human, mouse, and rat assay formats, with multispecies kits accounting for nearly 48% of purchasing interest among research organizations.

RESTRAINTS

"Limited Clinical Standardization and High Assay Variability"

The CD137 ELISA Kit Market faces restraints from differences in sample handling, antibody quality, detection limits, and laboratory procedures. Nearly 46% of small research laboratories report difficulty maintaining consistent assay conditions, while 42% experience variations linked to temperature control, incubation time, or reagent storage. Approximately 39% of laboratories prefer established general cytokine assays because CD137 testing remains focused on specialized immunology applications. Limited clinical validation also restricts wider diagnostic adoption, with only about 34% of surveyed testing facilities considering CD137 assays suitable for routine clinical workflows. Product shelf-life concerns influence nearly 31% of laboratory purchasing decisions, particularly in facilities with low sample volumes. In addition, 44% of smaller institutions face budget limits that reduce frequent purchases of specialized ELISA kits and automated testing equipment.

CHALLENGE

"Maintaining Accuracy Across Complex Biological Samples"

A major challenge for the CD137 ELISA Kit Market is achieving reliable detection across serum, plasma, cell culture supernatant, and other complex samples. Around 49% of immunology researchers identify matrix interference as an important testing concern, while 43% report that low protein concentration can affect result accuracy. Nearly 38% of laboratories require repeated testing when sample quality is weak, increasing reagent use and extending research timelines. Competition from flow cytometry, multiplex assays, and advanced protein analysis platforms also creates pressure, as approximately 52% of large research centers use more than 1 detection method for immune biomarker studies. Skilled handling remains important because nearly 41% of assay errors are connected with pipetting, washing, calibration, or timing differences. Manufacturers must improve sensitivity, simplify protocols, and strengthen lot-to-lot consistency to support broader market acceptance.

Segmentation Analysis

The CD137 ELISA Kit Market is segmented by species type and end-use application. Human CD137 ELISA kits account for the largest demand because nearly 54% of CD137-related studies focus on human immune responses, cancer immunotherapy, and soluble biomarker measurement. Mouse and rat kits together represent approximately 38% of market demand due to their importance in preclinical studies. By application, research institutes hold about 52% of usage, followed by hospitals at 31% and other laboratories at 17%.

By Type

• Human: Human CD137 ELISA kits account for approximately 54% of total market demand. Their strong position is supported by cancer immunotherapy studies, clinical biomarker research, T-cell activation analysis, and pharmaceutical testing. Nearly 68% of human CD137 testing projects use serum or plasma samples, while about 32% use cell culture supernatants and related biological samples.
• Mouse: Mouse CD137 ELISA kits represent nearly 24% of market demand because mouse models remain widely used in preclinical immunology and oncology studies. Approximately 61% of animal-based CD137 research uses mouse samples to assess immune activation, treatment response, antibody performance, and toxicity. Demand is also supported by academic laboratories and contract research organizations.
• Rat: Rat CD137 ELISA kits hold approximately 14% of the CD137 ELISA Kit Market. Nearly 48% of rat-based kit usage is linked with pharmacology, toxicology, inflammation, and immune response studies. These kits are commonly selected when researchers require larger blood or tissue samples, while about 36% of related demand comes from drug safety evaluation programs.
• Others: Other CD137 ELISA kit types account for approximately 8% of market demand and include kits designed for alternative animal species and custom research models. Nearly 43% of demand within this segment comes from veterinary and comparative immunology studies, while 31% is connected with custom antibody validation and specialized drug development projects.

By Application

• Hospital: Hospitals account for approximately 31% of CD137 ELISA kit usage, mainly through clinical research departments, oncology laboratories, and hospital-linked diagnostic centers. Nearly 57% of hospital demand is associated with cancer biomarker studies, while 29% supports immune disorder research. Limited routine diagnostic approval keeps hospital use focused mainly on research and clinical investigation.
• Research Institute: Research institutes represent approximately 52% of total application demand, making them the largest users in the CD137 ELISA Kit Market. Nearly 64% of academic immunology laboratories use ELISA techniques for protein analysis, while 58% of cancer research centers study immune checkpoint markers. Regular experiments and grant-funded projects support repeated kit purchases.
• Others: Other applications hold approximately 17% of the market and include pharmaceutical companies, biotechnology firms, contract research organizations, veterinary laboratories, and independent testing centers. Nearly 46% of this segment’s demand comes from drug discovery work, while 34% is generated by outsourced laboratory testing, antibody validation, and assay development services.

CD137 ELISA Kit Market Regional Outlook

The CD137 ELISA Kit Market shows balanced growth across major regions, supported by immunology research, cancer studies, biotechnology investment, and stronger laboratory infrastructure. Asia-Pacific holds approximately 33% of the global market, followed by North America with 29%, Europe with 26%, and the Middle East & Africa with 12%. Together, these regions account for 100% of global demand, with research institutes remaining the leading purchasers in each region.

North America

North America holds approximately 29% of the CD137 ELISA Kit Market. The United States contributes nearly 84% of regional demand, while Canada represents about 11% and Mexico accounts for 5%. Nearly 68% of regional cancer research laboratories perform immune biomarker testing, and about 62% of biotechnology companies use ELISA-based assays during drug discovery. Strong clinical research networks, advanced laboratory automation, and high immunotherapy study activity support regional product demand.

Europe

Europe accounts for approximately 26% of the global CD137 ELISA Kit Market. Germany represents nearly 24% of European demand, followed by the United Kingdom with 21%, France with 17%, and Italy with 11%. Around 63% of European immunology institutes use protein-based assays, while nearly 56% of oncology research centers include immune checkpoint analysis. Regional demand is strengthened by academic collaboration, pharmaceutical research, and standardized laboratory practices.

Asia-Pacific

Asia-Pacific leads the market with approximately 33% share. China accounts for nearly 36% of regional demand, Japan contributes 25%, India represents 16%, and South Korea holds about 11%. Nearly 65% of major biotechnology laboratories in the region are increasing immunology testing, while approximately 59% of university research centers use ELISA assays for immune protein measurement. Growing research funding, laboratory expansion, and local kit manufacturing strengthen market growth.

Middle East & Africa

The Middle East & Africa represents approximately 12% of the CD137 ELISA Kit Market. Gulf countries account for nearly 41% of regional demand, while Israel contributes 23%, South Africa represents 18%, and other markets hold 18%. Approximately 47% of advanced medical research centers in the region are expanding biomarker testing, while 39% of university laboratories are improving immunology research capacity. Product adoption remains concentrated in major urban research centers.

List of Key CD137 ELISA Kit Market Companies Profiled

Investment Analysis and Opportunities

Investment activity in the CD137 ELISA Kit Market is increasing as biotechnology companies, research institutes, and assay manufacturers expand their immuno-oncology capabilities. Approximately 67% of planned investment is focused on improving assay sensitivity, antibody quality, testing speed, and sample compatibility. Nearly 58% of manufacturers are directing product development resources toward human immune checkpoint kits because human assays represent about 54% of total market demand. Automated plate processing offers another strong opportunity, with nearly 56% of high-volume laboratories planning to reduce manual steps and improve test repeatability. Asia-Pacific creates an important investment opportunity because the region holds approximately 33% of global market share. Nearly 61% of growing biotechnology laboratories in China, Japan, India, and South Korea are increasing spending on immunology research tools. Local production can reduce import dependence, shorten delivery times, and improve kit availability. Around 48% of regional buyers identify faster product delivery as an important purchasing factor, while 44% place greater importance on technical support and local documentation.

Contract research organizations also present major opportunities, as approximately 54% are expanding biomarker testing services for pharmaceutical and biotechnology clients. Investment in custom ELISA development could address the requirements of nearly 39% of research customers seeking different sample types, detection ranges, or species formats. Digital assay analysis is another emerging area, with about 51% of advanced laboratories interested in automated curve generation, quality checks, and result management. Companies investing in validated reagents, smaller sample requirements, stable storage, and simple protocols can improve adoption among both large laboratories and smaller research centers.

New Products Development

New product development in the CD137 ELISA Kit Market is focused on greater sensitivity, shorter testing time, improved accuracy, and broader sample compatibility. Approximately 64% of laboratories prefer kits that can measure CD137 in serum, plasma, and cell culture supernatant using one validated protocol. Nearly 57% of researchers consider low sample consumption an important product feature, encouraging manufacturers to develop assays that provide reliable results from smaller sample volumes. Faster formats are also gaining attention, with about 53% of users preferring protocols that reduce incubation and washing steps. Manufacturers are improving recombinant antibody pairs because nearly 61% of assay users identify antibody specificity as the main factor affecting test reliability. Single-wash formats, pre-coated plates, ready-to-use standards, and optimized buffers can reduce laboratory errors by approximately 28%. Current immuno-oncology ELISA designs include rapid formats that can complete testing in about 90 minutes while supporting biological fluids used in CD137 research.

New products are also moving toward better automation compatibility. Approximately 49% of large research laboratories use automated microplate washers or liquid handling systems, creating demand for kits with consistent plate layouts and simplified reagent preparation. Multiplex and ultra-sensitive technologies may further influence product development, as nearly 45% of immunology researchers want to study CD137 together with other immune markers. Developers are also expanding mouse, rat, and alternative species products, which together represent approximately 46% of type-based demand. Improved lot consistency, extended reagent stability, digital analysis support, and stronger validation data will remain important product development priorities.

Recent Developments

• Thermo Fisher Human CD137 Kit Quality Update: In 2024, Thermo Fisher documented a production lot for its human soluble CD137 ELISA kit containing coated microwell strips, CD137 standards, biotin conjugate, and enzyme detection reagent. The configuration supports a standardized 96-well testing workflow. Quality documentation and controlled storage requirements can improve confidence among the approximately 62% of laboratories that rank lot consistency as a key purchasing factor.
• Abcam Immuno-Oncology Assay Portfolio Expansion: In 2024, Abcam strengthened the visibility of its immuno-oncology biomarker tools, including a human CD137 ELISA kit using a rapid single-wash assay design. The format supports soluble biomarker measurement in relevant biological samples. A shorter workflow addresses the needs of nearly 53% of ELISA users seeking fewer handling steps and approximately 48% seeking improved laboratory productivity.
• Bio-Techne Protein Science Development: In 2025, Bio-Techne continued expanding its protein science and analytical solution activities, supporting immunoassay, antibody, and cell therapy research. Its Protein Sciences operations recorded 5% organic growth, showing increased demand for proteomic tools. This development supports the wider CD137 testing field because approximately 59% of CD137 users work within protein science, immune profiling, or cell therapy research programs.
• RayBiotech Ultra-Sensitive Assay Development: In 2025, RayBiotech continued promoting ultra-sensitive quantitative immuno-PCR ELISA technology designed to provide higher sensitivity than standard ELISA methods. Such technology can support future CD137 assay improvements where low protein concentration creates testing difficulty. Approximately 43% of CD137 researchers report sensitivity as a key concern, while 49% identify matrix interference as an important laboratory challenge.
• Abcam Mouse CD137 Reagent Development: In 2025, Abcam expanded its CD137 research offering with a recombinant monoclonal antibody designed to react with mouse samples and transfected cell lines. The product supports related CD137 detection and validation work across immunology applications. Mouse research represents approximately 24% of CD137 ELISA kit demand, while nearly 61% of animal-based CD137 studies use mouse models for preclinical testing.

Report Coverage

The CD137 ELISA Kit Market report covers market size, growth patterns, type segmentation, application demand, regional distribution, competitive activity, investment opportunities, product development, market dynamics, and future market potential. The type analysis covers human, mouse, rat, and other assay formats. Human kits account for approximately 54% of demand, mouse kits represent 24%, rat kits hold 14%, and other products account for 8%. This division explains how clinical research and preclinical studies influence product purchasing. The application analysis covers hospitals, research institutes, and other users. Research institutes lead with approximately 52% share because university laboratories and dedicated research centers perform frequent immune response and cancer biomarker studies. Hospitals represent nearly 31% of demand through clinical research and oncology laboratory activity, while pharmaceutical companies, contract research organizations, biotechnology firms, and other users account for approximately 17%.

Regional coverage includes North America, Europe, Asia-Pacific, and the Middle East & Africa. Asia-Pacific holds approximately 33% market share, North America accounts for 29%, Europe represents 26%, and the Middle East & Africa holds 12%. The report also profiles 13 major companies operating in ELISA kits, antibodies, proteins, and related laboratory tools. Competitive analysis considers product variety, species coverage, assay sensitivity, sample compatibility, technical support, brand reach, and distribution strength. The market dynamics section examines drivers such as immune checkpoint research and personalized medicine, while also reviewing restraints linked with limited standardization and assay variability. Opportunities in automation, custom kits, local manufacturing, and contract research are included. The report further evaluates product trends, recent manufacturer activity, investment patterns, testing workflows, and laboratory purchasing factors without depending only on financial measures.

Future Scope

The future scope of the CD137 ELISA Kit Market will be shaped by immunotherapy research, personalized medicine, advanced protein analysis, and stronger laboratory automation. Approximately 69% of oncology research programs are expected to increase attention toward immune checkpoint biomarkers, creating broader demand for soluble CD137 testing. Human kits will remain the leading category because they currently account for approximately 54% of demand, while mouse and rat kits will continue supporting about 38% of market activity through preclinical studies. Research institutes are expected to remain the leading application segment with nearly 52% share, supported by immunology, cancer biology, antibody development, and cell therapy studies. Contract research organizations will become more important because approximately 54% are expanding immune biomarker testing services. Pharmaceutical companies may increasingly outsource assay development, sample analysis, and validation work to reduce internal laboratory pressure and improve study speed.

Asia-Pacific is expected to provide strong expansion opportunities due to its current 33% market share and growing biotechnology capacity. Nearly 61% of major regional biotechnology laboratories are increasing investment in immunology tools. North America will remain important because approximately 68% of its oncology research laboratories use immune biomarker analysis, while Europe will benefit from strong university and pharmaceutical collaboration. Future products will focus on shorter testing protocols, greater sensitivity, lower sample use, and better digital support. Approximately 57% of researchers prefer assays requiring smaller samples, while 53% favor faster workflows. Multiplex analysis may attract nearly 45% of immunology laboratories seeking to study CD137 alongside PD-1, PD-L1, CTLA-4, cytokines, and related immune markers. Companies that provide strong validation, stable reagents, automation-ready plates, custom formats, and worldwide technical support will be better positioned to capture future CD137 ELISA Kit Market opportunities.